logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Chronic Obstructive Airway Disease

    FiltersReset Filters
    12 results

    • arformoterol tartrate inhalation solution

      (Arformoterol Tartrate Inhalation Solution)
      Ritedose Pharmaceuticals, LLC
      Usage: Arformoterol Tartrate Inhalation Solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, via nebulization. It is not for acute COPD exacerbations or asthma treatment.

    • breo ellipta

      (fluticasone furoate and vilanterol trifenatate)
      GlaxoSmithKline LLC
      Usage: BREO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 5 years and older. It is not to be used for the relief of acute bronchospasm.

    • budesonide and formoterol fumarate dihydrate

      (Budesonide and Formoterol Fumarate Dihydrate)
      AstraZeneca Pharmaceuticals LP
      Usage: Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol is indicated for asthma treatment in patients aged 6 and older and for the maintenance treatment of COPD. It is used for patients not adequately controlled on asthma medications or requiring both an ICS and LABA, but not for acute bronchospasm relief.

    • formoterol fumarate inhalation solution

      (formoterol fumarate dihydrate)
      Ritedose Pharmaceuticals, LLC
      Usage: Formoterol Fumarate Inhalation Solution is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema. It is not suitable for treating acute COPD exacerbations or asthma.

    • ipratropium bromide and albuterol sulfate

      (Ipratropium Bromide and Albuterol Sulfate)
      Ritedose Pharmaceuticals, LLC
      Usage: Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is indicated for treating bronchospasm in COPD patients who require multiple bronchodilators.

    • nucala

      (mepolizumab)
      GlaxoSmithKline LLC
      Usage: NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.

    • perforomist

      (formoterol fumarate dihydrate)
      Mylan Specialty L.P.
      Usage: PERFOROMIST (formoterol fumarate) is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, administered twice daily. It is not intended for acute worsening of COPD or for asthma treatment.

    • roflumilast

      (Roflumilast)
      MAJOR PHARMACEUTICALS
      Usage: Roflumilast Tablets are indicated for reducing COPD exacerbation risk in patients with severe COPD and chronic bronchitis. It is not a bronchodilator and is not intended for acute bronchospasm relief. The starting dose is 250 mcg for the first four weeks and is not the therapeutic dose.

    • spiriva respimat

      (tiotropium bromide inhalation spray)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: Spiriva Respimat (tiotropium bromide) is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 6 and older, helping to reduce exacerbations. It is not intended for acute bronchospasm relief.

    • stiolto respimat

      (tiotropium bromide and olodaterol)
      Boehringer Ingelheim Pharmaceuticals Inc.
      Usage: STIOLTO RESPIMAT is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for acute COPD deteriorations or for the treatment of asthma.